Phase 3 Readout

SABS: Phase 3 Topline: Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inheri

Name: Phase 3 Topline: Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inheri
Start: 2029-08-01
End: 2029-08-01

August 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: August 1, 2029
Company: SAB BIOTHERAPEUTICS, INC. (SABS)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Efficacy and Safety of Gene Therapy rAAV-RPE65 (LX101) in Biallelic RPE65 Mutation-associated Inheri

August 1, 2029

SABS overview →

Company: SAB BIOTHERAPEUTICS, INC. (SABS)
Indication: Inherited Retinal Dystrophy Associated With RPE65 Mutations